Liver/Biliary Disorders News

Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.

Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.

Over three decades, changes to organ allocation policies were associated with reduced waitlist mortality and increased rates of liver transplant among children with pediatric acute liver failure, according to research in JAMA Surgery.

The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee.

Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.

Immunotherapy treatment may make liver transplant viable for patients with later-stage hepatocellular carcinoma provided they adhere to a 3-month waiting period, according to study results.

The FDA has granted breakthrough therapy designation to Boehringer Ingelheim’s survodutide for the treatment of adult patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or advanced fibrosis.

Significant variations in global rates of infection, culture-positivity and drug resistance serve as a “call to action” to streamline antibiotic use and improve outcomes among inpatients with cirrhosis, according to researchers.

Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.

The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.